TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation into a Vaccine to Treat HER2/neu Breast Cancer.

Addition of Class I antigen provides new advance in development of HER2/neu vaccines. April 16, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology. This antigen was discovered…

Details

TapImmune Appoints Dr Robert Florkiewicz as Senior Director of Molecular Biology & Virology

April 11, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that Robert Florkiewicz, Ph.D., has been appointed Senior Director of Molecular Biology & Virology. “Bob has a unique combination of skills and experience in the fields of virology and molecular biology that encompasses both the science and intellectual property landscapes” said Mark Reddish, Head…

Details

TapImmune Inc. to Present at BioPartnering North America. 10th Annual Event takes place in Vancouver British Columbia Feb 26-28 2012

February 27 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) a vaccine technologies company specializing in the development of innovative immunotherapeutics and vaccines in the areas of oncology and infectious disease, is pleased to announce that Dr. Glynn Wilson, Chief Executive Officer, will be presenting at the 10th Annual BioPartnering North America (BPN) in Vancouver, BC,…

Details

TapImmune to Open New Laboratories and Offices at 1551 Eastlake Ave. Comprehensive Lab Facilities Located in Seattle’s Newest Biotech Hub

January 18, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has signed a sub-lease for newly-renovated, state of the art laboratory and office space at 1551 Eastlake Avenue in South Lake Union — in the heart of Seattle’s vibrant biotech and medical community. The sublease was signed with Puget Sound Blood Center Research Institute and includes…

Details

TapImmune Appoints Mark Reddish to its Management Team as Vice President Product Development

Former executive at ID Biomedical and Biomira Inc brings broad experience and expertise in Cancer and Biodefense product development November 22, 2011, Seattle WA, TapImmune Inc. (OTCBB: TPIV), is pleased to announce that Mark Reddish has joined its Management Team as Vice President of Product Development. Mark was formerly Vice President of Product Development and…

Details